Skip to main content

The Globe and Mail

Valeant adds 250 staff to Salix sales force

The headquarters of Valeant Pharmaceuticals International Inc is seen in Laval, Que., on Nov. 9, 2015.

Christinne Muschi/Reuters

Valeant Pharmaceuticals said Monday it has grown the sales force at its Salix drug business by about 250 people over the past three months.

The company, based in Laval, Que., said the 40-per-cent increase to its existing sales staff will help grow market share and build relationships with doctors that may prescribe its gastrointestinal drugs.

One of the Salix drugs, Xifaxan, is for treating irritable bowel syndrome with diarrhea. Another Salix gastrointestinal drug, Relistor, is for treating opioid-induced constipation.

Story continues below advertisement

Valeant purchased Salix in April, 2015, for $11.1-billion (U.S.). It wrote down Salix's value in November by $1.05-billion in the third quarter.

In December, Valeant CEO Joseph Papa said the company would try to expand the sale of prescriptions for products like Xifaxan by launching a program directed at primary care physicians.

Report an error Licensing Options

The Globe invites you to share your views. Please stay on topic and be respectful to everyone. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

We’ve made some technical updates to our commenting software. If you are experiencing any issues posting comments, simply log out and log back in.

Discussion loading… ✨